Details of the Drug

General Information of Drug (ID: DMNVZDT)

Drug Name
ISIS-FGFR4
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 2 [1]
Drug Type
Antisense drug
Cross-matching ID
TTD ID
D0SL8T

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
FGFR4 messenger RNA (FGFR4 mRNA) TT1KX2S FGFR4_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02476019) A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients.
2 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
5 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.